HTAi’s Presidents have played crucial roles in the growth and maturation of the Society, and each has made notable contributions to the promoting the development and use of HTA worldwide. Since its founding in 2003, We have grown into a thriving network with close to 1,300 members from around the world, and has become a major hub for global collaboration in HTA. Below are our Past Presidents in the order of their tenure, beginning with the most recent. The following biographies are circa the first year of each President’s tenure.

Sean Tunis, 2017-19

Sean Tunis, MD, MSc, is the Founder, President and Chief Executive Officer of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP is an independent, non-profit organization that provides a neutral platform for multi-stakeholder collaborations that are focused on improving the quality, relevance and efficiency of clinical research. His work currently focuses on expanding infrastructure for the conduct of pragmatic clinical trials within the health care delivery systems, developing condition-specific evidentiary standards for reimbursement, and promoting greater engagement of patients and consumers in clinical research. Tunis serves on the Board of HTAi, the Health Sciences Policy Council for ISPOR and a number of other advisory boards for public and private sector organizations focused on issues of comparative effectiveness, innovation, health technology assessment, evidence-based medicine, clinical research and reimbursement.

Guy Maddern, 2015-17

Guy Maddern is the RP Jepson Professor of Surgery at the University of Adelaide and Director of Surgery at The Queen Elizabeth Hospital and Royal Adelaide Hospital. He was trained at the University of Adelaide and became a Fellow of the Royal Australasian College of Surgeons in 1989. His clinical interests include the physiological impact of laparoscopic surgery, and more recently the development of techniques to manage metastatic hepatic disease. He has over 400 publications in scientific journals and has contributed to over a dozen surgical texts.

At the commencement of 1996, Maddern was appointed Director of the Clinical Development Research Centre, now the Basil Hetzel Institute for Translational Health Research, at The Queen Elizabeth Hospital charged with the responsibility of defining the future direction and development of research within The Queen Elizabeth Hospital campus.

In November 1997, he was appointed Surgical Director of the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP- S). This organisation, funded by the Federal Government through the Royal Australasian College of Surgeons, is a programme designed to perform rigorous assessments on the safety and efficacy of new procedures and technologies available in surgical practice, and feedback this information to surgeons and the community.

Carole Longson, 2013-15

Carole Longson is Director of the Centre for Health Technology Evaluation and an Executive Director at NICE. She has a doctorate in Pharmacology and spent 8 years in drug discovery at GlaxoSmithKline on the identification and development of novel pharmaceuticals across multiple therapeutic areas. She has undertaken many academic secondments including The Institute of Molecular Biology in Geneva and the University of California in Irvine, USA. She contributes to international policy forums, including the WHO advisory groups on Priority Medical Devices and Innovative Technologies and is President of Health Technology Assessment International. She also is a member of the scientific committee of the European Commission Innovative Medicines Initiative

Her research interests lie in the scientific methodologies of health technology assessment used in the context of health policy decision making.

Clifford Goodman, 2011-13

Clifford Goodman, PhD, is a Vice President at The Lewin Group, a health care policy and human services consulting firm located near Washington, DC. He has 30 years of experience in health care evaluation, including HTA, evidence-based health care, comparative effectiveness research, health economics, and studies pertaining to health care innovation, regulation, and payment. He directs studies and projects for an international range of government agencies; pharmaceutical, biotechnology, and medical device companies; health care provider institutions; and professional, industry, and patient advocacy groups. His recent work has involved studies in oncology, cardiovascular disease, diabetes, obesity, end-stage renal disease, pandemic influenza, follow-on biologics, wound care, health information technology, pharmacogenomics, diagnostic testing, and organ transplantation. He directed a Lewin team that provided technical support for the US Federal Coordinating Council for Comparative Effectiveness Research (including its Report to the President and The Congress, 2009). For the US Agency for Healthcare Research and Quality (AHRQ), he directed the Evidence-based Practice Centers Coordinating Center at The Lewin Group (2002-08). Dr. Goodman is chair (through May 2011) of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) for the US Centers for Medicare and Medicaid Services (CMS). He has testified to Congress on issues pertaining to Medicare coverage of health care technology. Earlier in his career, as a National Research Council Fellow and later as director of the Council on Health Care Technology, he managed and staffed a series of HTA projects at the Institute of Medicine, including the landmark study, Assessing Medical Technologies. Subsequently, he was a visiting researcher in Stockholm at the Swedish Council on Technology Assessment in Health Care (SBU). He is a founding board member of HTAi and is a Fellow of the American Institute for Medical and Biological Engineering. He serves on the editorial boards of the International Journal of Technology Assessment in Health Care and the American Journal of Managed Care. He did his undergraduate work at Cornell University, received a master’s degree from the Georgia Institute of Technology, and earned his doctorate from the Wharton School of the University of Pennsylvania.

Laura Sampietro-Colom, 2009-11

Laura Sampietro-Colom is Head of the Health Technology Assessment (HTA) Unit in the Research and Innovation Directorate at the Hospital Clinic of Barcelona, a high-tech hospital and a reference for health care, research, innovation and medical training in Spain. She is also the Chair-Elect of the HTAi Policy Forum and Chair of the first Latin-American HTAi Policy Forum. Prior to this, she was the General Director of Information Systems, Projects and Evaluation of the Catalan Health Institute, the leading provider of public health services in the Region of Catalonia and the Director of the Strategic Planning Unit of Health Services within the Planning and Evaluation Directorate of the Ministry of Health of Catalonia, Spain.

Laura has over 20 years of experience in evaluative research, specifically in HTA and was one of the founders of the Catalan Agency for Health Technology Assessment (nowadays AQuAS). She was the Founding member of the International Society for Health Technology Assessment (HTAi), serving on the Board of Directors since its foundation and being its President for two years. Responsible for the development of one of the research lines of the first international project conducted by the International Network of Agencies for Health Technology Assessment (INAHTA), she has also worked in several EU HTA projects; including the coordination of AdHopHTA, the first EU funded project on hospital-based HTA. She has been temporary adviser of the United Nations Agencies WHO and PAHO. She advises on HTA strategies to public and private organisations worldwide. She is also mentoring the development of innovations under the umbrella of a capital risk/foundation program (“Caixaimpulse”).

Laura is a trained Medical Doctor; Board Certified Specialist in Preventive Medicine and Public Health (University of Barcelona) and holds a PhD in Medicine and Surgery by the Autonomous University of Barcelona, and a Master of Science in Public Health by the Rolling School of Public Health (Emory University, Atlanta, USA) as well as post graduate courses in Health Economics, Management of Health Care Institutions and Management of Innovation & Science. Throughout, her work has focused on the development, identification, management and transfer of information to advise on the designing of strategies and policies in the areas of assessment, planning and access of medical devices, drugs, surgical procedures and other health care technologies as well as health care programs.

Reiner Banken, 2007-09

Reiner Banken obtained his medical degree from Universit de Montral, where he also earned a master’s degree in Community Health. Consultant Researcher for AETMIS (the HTA agency for the province of Quebec) since 1998, he holds the position of Deputy Chief Executive Officer, Development and Partnerships since July 2005. He worked as an emergency physician for five years and as a specialist in public health for 12 years, including serving as Public Health Director for Qubec’s Laurentian region.

Berit Mørland, 2005-07

Dr. Mørland is Deputy Director General of the Norwegian Knowledge Centre for the Health Services. She was responsible for establishing the Norwegian Centre for Health Technology Assessment, which she has managed for the past 7 years, and was Director of the Norwegian Medical Research Council. Previously, she served as a clinician, taught and conducted research in universities, and worked in the pharmaceutical industry.

Her current interest in international collaboration has led to membership in committees in the EU, World Health Organization (WHO), North Atlantic Trade Organization (NATO), and the OECD. She has also been extensively involved in international HTA initiatives, formerly serving as Chair of INAHTA. Dr. Mrland is a Doctor of Dental Surgery and holds a PhD in Immunology

Chris Henshall, 2003-05

Chris Henshall is Director of the Science and Engineering Base Group in the Office of Science and Technology in the Department of Trade and Industry in London, where he is responsible for around 3b (US $5b) per annum of government support for research and innovation. Before joining the Department of Trade and Industry, Dr. Henshall served as Deputy Director of Research and Development in the Department of Health. During his tenure there, he was closely involved in establishing the NHS HTA Programme, the National Institute for Clinical Excellence, and, with colleagues in other countries, INAHTA. Over the years, he has also been involved in various initiatives to promote and co-ordinate HTA across Europe.

Dr. Henshall is an Honorary Professor in the Department of Public Health and Policy in the London School of Hygiene and Tropical Medicine. Dr. Henshall has an MA and PhD from the University of Cambridge and an MA from the University of Nottingham.

Alicia Granados, 2003

Up to January 2003, Dr. Granados was President and Chief Executive Officer of the Catalan Institute of Health. In this position, she managed Catalonia’s largest public health care provider, which comprises 11 large hospitals and more than 300 primary health-care centres and local consulting rooms. From 1994 to 1997, Dr. Granados was Director of the Catalan Agency for Health Technology Assessment, where she still remains a member of the Board. This agency generates health technology information to help inform decision-making in the Catalan Health Service, the Catalan Department of Health and Social Security, hospitals belonging to the Catalan Health Institute, and private health care organizations. Dr. Granados is also an Associate Professor in the Department of Medicine at the University of Barcelona.

From 2002 to 2003, she was President of the Board of Directors of the International Society of Technology Assessment in Health Care, following which she chaired the international committee assembled to create HTAi.

Dr. Granados completed both her medical degree and her Doctor of Philosophy in Medicine and Surgery at the University of Barcelona.